News of an analyst's price-target hike plus a new round of capital-raising were the sparks that ignited Janux Therapeutics (NASDAQ: JANX) stock on Wednesday. The clinical-stage biotech's share price ended...
Shares of Janux Therapeutics JANX surged 49% on Tuesday after the company posted updated interim results from a phase Ib study, which is evaluating JANX007 in patients with advanced or metastatic prostate...
David Alan Campbell, the President and CEO of $JANX ($JANX), sold 15,000 shares of the company on 12-03-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 5.8%...
The S&P 500 Index ($SPX ) (SPY ) Tuesday closed up +0.05%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.17%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.31%. Stocks on Tuesday...
The treatment, a tumor-activated T-cell engager, leverages the immune system by recruiting white blood cells to attack cancer cells.
The S&P 500 Index ($SPX ) (SPY ) today is down -0.22%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.25%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.23%. Stocks today are posting...
The S&P 500 Index ($SPX ) (SPY ) today is down -0.07%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.15%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.09%. Stocks today are slightly...
David Alan Campbell, the President and CEO of $JANX ($JANX), sold 6,719 shares of the company on 11-25-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 2.5%...
These small-cap biotech stocks are rallying hard in 2024, and still have room to keep leading the RUT higher.
/CNW/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding...